RAVE crypto crashed over 44% to nearly $10 earlier today before backpedalling on some of its losses as investors bought the dip.

According to data from CoinGecko, RaveDAO (RAVE) price skyrocketed over 5,300% this week to an all-time high of $19.54 on Wednesday, becoming the best-performing crypto asset among the top 100 cryptocurrencies across daily, weekly, and monthly timeframes.

The token price rose due to a massive short squeeze triggered by a sudden surge in social media engagement and speculative retail interest. As prices rose higher, short sellers were forced to liquidate their positions, which added further fuel to the upward momentum and created a feedback loop of buying pressure.

It was also supported by the recent listing of RAVE on several secondary exchanges, which significantly boosted liquidity and accessibility for new traders.

Following the sharp rally, the token fell nearly 45% to near $10 as investors booked profits following the massive surge. It is quite common for investors to book some profits, especially after such an unprecedented vertical move that left the asset in overbought territory.

As of press time, the token has rebounded by nearly 50% back to $15, raising eyebrows over whether bulls are attempting to push the token to a new all-time high.

A look at the token futures market seems to suggest that market conviction remains incredibly high despite the volatility. Notably, the total futures open interest of the token rose over 30% to $470 million in the past 24 hours. This suggests that a majority of traders are leaning towards bullish bets, likely expecting the price to recover amid recent U.S. Iran war ceasefire news, which has improved overall market sentiment.

At the same time, the weighted funding rate of the token is exiting the red zone, a sign that the extreme bearishness of short sellers is fading and long positions are becoming more attractive again.

On the spot market, nearly over $7 million was withdrawn from exchanges over the past day. This means that investors were likely moving their holdings to their cold wallets, likely expecting further price appreciation and intending to hold for the long term.

Amidst these developments, its price action charts also seem to hint that the token is preparing for its next height, potentially to a new all-time high above $20.

On the 4-hour chart, RaveDAO price was trading above all of the simple moving averages. This means the immediate trend remains firmly bullish. At the same time, the MACD lines are drawing closer to a bullish crossover, which would confirm that the temporary correction has ended and the next leg of the rally is beginning.

Key Takeaways

• Abbott shares plunge 4.34% even as revenue surpasses forecasts and earnings hold steady
• Operating margins compress significantly as expenses outpace revenue expansion
• Company slashes annual earnings forecast, sparking investor concerns
• Exact Sciences acquisition strengthens oncology portfolio while pressuring near-term profits
• First-quarter results exceed expectations, yet margin weakness drives stock decline

Shares of Abbott Laboratories (ABT) tumbled in pre-market hours despite delivering robust first-quarter revenue figures and maintaining steady earnings. The healthcare giant’s decision to lower its full-year profit outlook coupled with deteriorating operating margins spooked investors, raising red flags about the company’s ability to maintain profitability. Trading at $97.10, the stock shed 4.34% as sellers dominated following the earnings announcement.

Abbott Laboratories, ABT

First Quarter Results Show Solid Top-Line Growth

Abbott Laboratories posted first-quarter sales of $11.16 billion, surpassing Wall Street projections by 1.3%. The healthcare company achieved 7.8% year-over-year sales growth, demonstrating consistent performance across its diverse healthcare divisions. Organic growth trends remained measured, suggesting the underlying business expansion progressed at a sustainable pace.

On the earnings front, Abbott reported adjusted earnings of $1.15 per share, perfectly aligning with analyst forecasts. This represented an improvement from the $1.09 per share recorded in the comparable quarter last year, showing incremental profit gains. However, meeting expectations precisely without upside failed to generate enthusiasm among market participants.

The diversified healthcare manufacturer operates across multiple segments including diagnostics, medical devices, nutritional products, and established pharmaceuticals. Ongoing innovation initiatives and market expansion strategies have supported consistent quarterly revenue growth. Yet the company’s five-year average annual revenue growth of just 3.9% trails more dynamic competitors in the healthcare space.

Profitability Challenges and Guidance Reduction

Abbott disclosed an adjusted operating margin of 12% for the quarter, representing a substantial decline from the 16.3% margin achieved one year earlier. Expense growth exceeded sales growth, undermining operational efficiency throughout the period. This margin deterioration sparked concerns regarding the company’s cost management capabilities and economies of scale.

Management also trimmed its full-year adjusted earnings per share guidance to a midpoint of $5.48. This downward revision represented a 3.4% decrease compared to previous forecasts, suggesting more conservative internal assumptions. The guidance cut proved instrumental in driving the negative market response to otherwise solid quarterly results.

Examining the longer-term trend, Abbott’s operating margin has contracted by 6.2 percentage points over the past five years, indicating persistent profitability headwinds. Annual earnings per share growth has averaged merely 3.8%, tracking closely with the company’s moderate revenue trajectory. These metrics underscore Abbott’s struggle to achieve meaningful operating leverage despite its considerable scale.

Growth Initiatives and Future Projections

The company recently finalized its purchase of Exact Sciences, bolstering its capabilities in cancer diagnostics. This strategic transaction adds a promising high-growth business line expected to accelerate future sales. However, the acquisition simultaneously introduces short-term earnings dilution, which factored into the revised guidance framework.

Abbott continues investing in medical technology innovation through strategic partnerships and clinical research in cardiovascular health and diabetes management. Recent product trials have demonstrated enhanced clinical outcomes, reinforcing the company’s relevance in evolving healthcare markets. These investments lay groundwork for gradual improvement in growth trajectories.

Wall Street analysts project Abbott’s revenue will expand by 11.1% over the coming twelve months, suggesting accelerating momentum ahead. Forecasted earnings per share growth of 8.5% indicates expectations for profitability recovery. Nevertheless, immediate margin pressures and the reduced guidance continue to create headwinds for investor sentiment in the near term.

AllUnity, a regulated European stablecoin issuer, is expanding its euro-pegged stablecoin, EURAU, across major decentralized exchanges (DEXs).

The company announced Thursday that its EURAU stablecoin is entering liquidity pools across major DEXs, including Uniswap, currently the largest decentralized exchange by trading volumes.

The rollout includes two EURAU trading pairs, one against Tether USDt (USDT) on Ethereum, and another against USDT0 — an omnichain version of USDT — on the Tempo blockchain. It also includes the EURAU/USDT pair on Solana via the Raydium DEX.

AllUnity’s DEX push comes as uncertainty persists over how far decentralized finance (DeFi) falls within the scope of the European Union’s Markets in Crypto-Assets Regulation (MiCA) regime.

While DeFi is generally considered outside the scope of the framework, the European Central Bank last month questioned whether decentralized autonomous organizations are decentralized enough to remain outside MiCA’s regulatory perimeter.

AllUnity built EURAU under BaFin licence

AllUnity operates as a MiCA-compliant stablecoin issuer after obtaining an Electronic Money Institution license from the German Federal Financial Supervisory Authority (BaFin) in July 2025.

AllUnity launched EURAU on July 31, 2025. The token remains small by market capitalization compared with the largest euro stablecoins.

AllUnity has been expanding the presence of its EURAU stablecoin across exchanges, with listings on centralized exchanges (CEXs) such as Bullish as well as decentralized ones like Aerodrome. Aerodrome became the first DEX integration for EURAU in December 2025.

Dollar stablecoins still dominate

The MiCA framework, which entered into full force in late 2024, has often been seen as a tool to address the dominance of stablecoins pegged to the US dollar.

Some major issuers, including Tether, have openly criticized the framework and declined to seek compliance in the EU, citing concerns over its requirements, which led to some compliant exchanges delisting its USDT stablecoin.

Some banking officials have since said MiCA may not be sufficient to address the dominance of US dollar-pegged stablecoins, which still account for 97% of the $316 billion market globally, according to CoinGecko.

Related: Bank of France calls for tougher MiCA limits on stablecoin payments

As AllUnity’s DEX push also involves major US dollar stablecoins, it remains unclear how regulators will respond to these developments.

“Expanding EURAU liquidity across DEXs is an important step in building a robust and accessible euro liquidity layer,” AllUnity’s executive Rupertus Rothenhäuser said, adding:

“We’re enabling seamless euro — dollar trading, empowering institutions and liquidity providers to participate in deep, efficient markets.”

Cointelegraph contacted AllUnity for comment regarding potential conflicts with the EU regulation but did not receive a response at the time of publication.

Magazine: How crypto laws changed in 2025 — and how they’ll change in 2026